CCA: The little-known, rare cancer of the biliary tract (ESMO 2022)
Professor Filippo de Braud
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano, Milan, Italy
The challenges associated with diagnosing intrahepatic CCA for targeted therapies (ESMO 2022)
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
Panel discussion / Q&A (ESMO 2022)
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Dr David Malka
Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France
INSERM U1279, Villejuif, Université Paris-Saclay, France
INSERM U1279, Villejuif, Université Paris-Saclay, France
Dr Antoine Hollebecque
Gustave Roussy, Villejuif, France
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
Professor Filippo de Braud
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano, Milan, Italy
Overcoming diagnostic challenges associated with CCA (ESMO GI 2022)
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Optimising molecular profiling in CCA (ESMO GI 2022)
Professor John Bridgewater
Clinical Professor, University College London Cancer Institute, London, UK
ESMO clinical practice guidelines and chemotherapy options in 2022 (ESMO GI 2022)
Professor Arndt Vogel
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)
Dr Nicola Normanno
Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy
Panel discussion / Q&A (ESMO GI 2022)
Professor Arndt Vogel
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
Professor John Bridgewater
Clinical Professor, University College London Cancer Institute, London, UK
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Professor Eric Van Cutsem
University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium
KU Leuven, Belgium
I see CCA today (2022)
World CCA Day (12 February 2022), organised by the Global CCA Alliance, is an international effort to raise
awareness of CCA. The purpose of Rare Disease Day (28 February 2022) is to raise awareness and generate
change for the 300 million people worldwide living with a rare disease.1 To support these initiatives, we asked
a patient with CCA and a multidisciplinary panel of CCA experts to express how they #SeeCCA today.
Reference: 1. Nguengang Wakap S, et al. Eur J Hum Genet. 2020;28:165–73.
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Phil Preston
Patient,
UK
UK
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
Dr Joachim Mertens
University Hospital Zürich,
Zürich, Switzerland
Zürich, Switzerland
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Professor Thomas Gruenberger
Sigmund Freud University,
Vienna, Austria
Vienna, Austria
Professor Bruno Sangro
Director, Liver Unit & Co-Director, HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain
Dr Teresa Macarulla
Vall d’Hebron University Hospital,
Barcelona, Spain
Barcelona, Spain
Dr Ana Vivancos
Vall d’Hebron Institute of Oncology,
Barcelona, Spain
Barcelona, Spain
Glenda O’Connor
Lead Dietician,
The Princess Grace Hospital,
London, UK
The Princess Grace Hospital,
London, UK
Optimising the multidisciplinary team for CCA management (ESMO 2021)
Dr David Malka
Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France
INSERM U1279, Villejuif, Université Paris-Saclay, France
INSERM U1279, Villejuif, Université Paris-Saclay, France
When could “cancer of unknown primary” be CCA? (ESMO 2021)
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Perspectives on precision medicine in CCA (2021)
Listen to Professor Eric Van Cutsem and Dr Angela Lamarca provide expert perspectives on key questions in precision medicine and molecular testing in advanced CCA
Professor Eric Van Cutsem
University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium
KU Leuven, Belgium
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
Importance of biomarkers in CCA (ESMO GI 2021)
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
CCA: under the spotlight (2021)
This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease
Dr Teresa Macarulla
Vall d’Hebron University Hospital,
Barcelona, Spain
Barcelona, Spain
Dr Joachim Mertens
University Hospital Zürich,
Zürich, Switzerland
Zürich, Switzerland
Dr Angela Lamarca
Fundación Jiménez Díaz University Hospital, Spain
Dr Coralie Sayag
Former Medical Director Solid Tumours,
Region Europe, Incyte Biosciences International Sàrl (01 May 2020 – 31 May 2022)
Region Europe, Incyte Biosciences International Sàrl (01 May 2020 – 31 May 2022)
Importance of molecular profiling in patients with CCA (ESMO 2020)
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Importance of performing biopsies in patients with CCA (ESMO 2020)
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)
Professor Lorenza Rimassa
Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Professor Juan Valle
University of Manchester & The Christie, Manchester, UK
Professor Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Unmet needs in CCA (ESMO 2020)
Helen Morement
CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK
Overview of CCA (ILCA 2020)
Professor Bruno Sangro
Director, Liver Unit & Co-Director, HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain
All videos in this category
CCA: The little-known, rare cancer of the biliary tract (ESMO 2022)
The challenges associated with diagnosing intrahepatic CCA for targeted therapies (ESMO 2022)
Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)
Panel discussion / Q&A (ESMO 2022)
Overcoming diagnostic challenges associated with CCA (ESMO GI 2022)
Optimising molecular profiling in CCA (ESMO GI 2022)
ESMO clinical practice guidelines and chemotherapy options in 2022 (ESMO GI 2022)
Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)
Panel discussion / Q&A (ESMO GI 2022)
I see CCA today (2022)
Optimising the multidisciplinary team for CCA management (ESMO 2021)
When could “cancer of unknown primary” be CCA? (ESMO 2021)
Perspectives on precision medicine in CCA (2021)
Importance of biomarkers in CCA (ESMO GI 2021)
CCA: under the spotlight (2021)
Importance of molecular profiling in patients with CCA (ESMO 2020)
Importance of performing biopsies in patients with CCA (ESMO 2020)
Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)
Unmet needs in CCA (ESMO 2020)
